Complex I: Inhibitors, inhibition and neurodegeneration

Experimental Neurology

Volumn 224, Issue 2, 2010, Pages 331-335

  Schapira, A H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Annonacin; Complex 1; Mitochondria; Mitochondrial DNA; MPTP; Parkinson's disease; Tau

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANNONACIN; BULLATACIN; COMPLEX I INHIBITOR; ENZYME INHIBITOR; FRATAXIN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MITOCHONDRIAL DNA; PETHIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; TAU PROTEIN; TRANSFER RNA; UBIDECARENONE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN DISEASE; BRAIN METABOLISM; COMPLEX I DEFICIENCY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; ENZYME INHIBITION; FRONTOTEMPORAL DEMENTIA; GENE DELETION; GENE MUTATION; GUADELOUPE; HUMAN; MITOCHONDRIAL RESPIRATION; MYOPATHY; NERVE DEGENERATION; NONHUMAN; NOTE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; TAUOPATHY;

ANIMALS; CELL DEATH; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX I; ENVIRONMENTAL POLLUTANTS; FURANS; HUMANS; HUNTINGTON DISEASE; LACTONES; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSONIAN DISORDERS; TAUOPATHIES;

EID: 77954657877     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.03.028     Document Type: Note

References (62)

1. Albers D.S., Augood S.J., Park L.C., Browne S.E., Martin D.M., Adamson J., Hutton M., Standaert D.G., Vonsattel J.P., Gibson G.E., Beal M.F. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J. Neurochem. 2000, 74:878-881.
2. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 2006, 38:515-517.
3. Berrisford J.M., Sazanov L.A. Structural basis for the mechanism of respiratory complex I. J. Biol. Chem. 2009, 284:29773-29783.
4. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
5. Bradley J.L., Blake J.C., Chamberlain S., Thomas P.K., Cooper J.M., Schapira A.H. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 2000, 9:275-282.
6. Caparros-Lefebvre D., Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 1999, 354:281-286.
7. Caparros-Lefebvre D., Sergeant N., Lees A., Camuzat A., Daniel S., Lannuzel A., Brice A., Tolosa E., Delacourte A., Duyckaerts C. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002, 125:801-811.
8. Champy P., Hoglinger G.U., Feger J., Gleye C., Hocquemiller R., Laurens A., Guerineau V., Laprevote O., Medja F., Lombes A., Michel P.P., Lannuzel A., Hirsch E.C., Ruberg M. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem. 2004, 88:63-69.
9. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 1992, 58:786-789.
10. Cock H.R., Tabrizi S.J., Cooper J.M., Schapira A.H. The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy. Ann. Neurol. 1998, 44:187-193.
11. Cooper J.M., Mann V.M., Schapira A.H. Analyses of mitochondrial respiratory chain function and mitochondrial DNA deletion in human skeletal muscle: effect of ageing. J. Neurol. Sci. 1992, 113:91-98.
12. Cooper J.M., Daniel S.E., Marsden C.D., Schapira A.H. l-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Mov. Disord. 1995, 10:295-297.
13. David D.C., Hauptmann S., Scherping I., Schuessel K., Keil U., Rizzu P., Ravid R., Drose S., Brandt U., Muller W.E., Eckert A., Gotz J. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005, 280:23802-23814.
14. Endo T., Yamano K. Transport of proteins across or into the mitochondrial outer membrane. Biochim. Biophys. Acta 2009, Electronic publication ahead of print.
15. Escobar-Khondiker M., Hollerhage M., Muriel M.P., Champy P., Bach A., Depienne C., Respondek G., Yamada E.S., Lannuzel A., Yagi T., Hirsch E.C., Oertel W.H., Jacob R., Michel P.P., Ruberg M., Hoglinger G.U. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J. Neurosci. 2007, 27:7827-7837.
16. Goedert M., Ghetti B., Spillantini M.G. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann. N. Y. Acad. Sci. 2000, 920:74-83.
17. Golbe L.I., Rubin R.S., Cody R.P., Belsh J.M., Duvoisin R.C., Grosmann C., Lepore F.E., Mark M.H., Sachdeo R.C., Sage J.I., Zimmerman T.R. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 1996, 47:148-154.
18. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
19. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 1995, 37:714-722.
20. Hollerhage M., Matusch A., Champy P., Lombes A., Ruberg M., Oertel W.H., Hoglinger G.U. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp. Neurol. 2009, 220:133-142.
21. Houlden H., Baker M., Morris H.R., MacDonald N., Pickering-Brown S., Adamson J., Lees A.J., Rossor M.N., Quinn N.P., Kertesz A., Khan M.N., Hardy J., Lantos P.L., St George-Hyslop P., Munoz D.G., Mann D., Lang A.E., Bergeron C., Bigio E.H., Litvan I., Bhatia K.P., Dickson D., Wood N.W., Hutton M. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001, 56:1702-1706.
22. Jenkins B.G., Koroshetz W.J., Beal M.F., Rosen B.R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993, 43:2689-2695.
23. Kraytsberg Y., Kudryavtseva E., McKee A.C., Geula C., Kowall N.W., Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38:518-520.
24. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol. 1992, 32:782-788.
25. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
26. Lannuzel A., Michel P.P., Hoglinger G.U., Champy P., Jousset A., Medja F., Lombes A., Darios F., Gleye C., Laurens A., Hocquemiller R., Hirsch E.C., Ruberg M. The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 2003, 121:287-296.
27. Lannuzel A., Hoglinger G.U., Verhaeghe S., Gire L., Belson S., Escobar-Khondiker M., Poullain P., Oertel W.H., Hirsch E.C., Dubois B., Ruberg M. Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?. Brain 2007, 130:816-827.
28. Leonard J.V., Schapira A.H. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 2000, 355:299-304.
29. Leonard J.V., Schapira A.H. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet 2000, 355:389-394.
30. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
31. Lodi R., Cooper J.M., Bradley J.L., Manners D., Styles P., Taylor D.J., Schapira A.H. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA 1999, 96:11492-11495.
32. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 2000, 48:72-76.
33. Luoma P.T., Eerola J., Ahola S., Hakonen A.H., Hellstrom O., Kivisto K.T., Tienari P.J., Suomalainen A. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 2007, 69:1152-1159.
34. Macaskill A.F., Kittler J.T. Control of mitochondrial transport and localization in neurons. Trends Cell Biol. 2009, Electronic publication ahead of print.
35. Mancuso M., Orsucci D., Siciliano G., Murri L. Mitochondria, mitochondrial DNA and Alzheimer's disease. What comes first?. Curr. Alzheimer Res. 2008, 5:457-468.
36. Mann V.M., Cooper J.M., Javoy-Agid F., Agid Y., Jenner P., Schapira A.H. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990, 336:749.
37. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 1994, 36:876-881.
38. Morgan-Hughes J.A., Schapira A.H., Cooper J.M., Clark J.B. Molecular defects of NADH-ubiquinone oxidoreductase (complex I) in mitochondrial diseases. J. Bioenerg. Biomembr. 1988, 20:365-382.
39. Morgan-Hughes J.A., Sweeney M.G., Cooper J.M., Hammans S.R., Brockington M., Schapira A.H., Harding A.E., Clark J.B. Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype. Biochim. Biophys. Acta 1995, 1271:135-140.
40. Morris A.A., Taanman J.W., Blake J., Cooper J.M., Lake B.D., Malone M., Love S., Clayton P.T., Leonard J.V., Schapira A.H. Liver failure associated with mitochondrial DNA depletion. J. Hepatol. 1998, 28:556-563.
41. Morris H.R., Janssen J.C., Bandmann O., Daniel S.E., Rossor M.N., Lees A.J., Wood N.W. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 1999, 66:665-667.
42. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci. 1985, 36:2503-2508.
43. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26:719-723.
44. Schapira A.H. Human complex I defects in neurodegenerative diseases. Biochim. Biophys. Acta 1998, 1364:261-270.
45. Schapira A.H. Mitochondrial disease. Lancet 2006, 368:70-82.
46. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7:97-109.
47. Schapira A.H., Cooper J.M., Morgan-Hughes J.A., Patel S.D., Cleeter M.J., Ragan C.I., Clark J.B. Molecular basis of mitochondrial myopathies: polypeptide analysis in complex-I deficiency. Lancet 1988, 1:500-503.
48. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
49. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
50. Schapira A.H., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., Marsden C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 1990, 55:2142-2145.
51. Smith P.R., Cooper J.M., Govan G.G., Harding A.E., Schapira A.H. Smoking and mitochondrial function: a model for environmental toxins. Q.J. Med. 1993, 86:657-660.
52. Smith P.R., Cooper J.M., Govan G.G., Harding A.E., Schapira A.H. Platelet mitochondrial function in Leber's hereditary optic neuropathy. J. Neurol. Sci. 1994, 122:80-83.
53. Stamelou M., Reuss A., Pilatus U., Magerkurth J., Niklowitz P., Eggert K.M., Krisp A., Menke T., Schade-Brittinger C., Oertel W.H., Hoglinger G.U. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov. Disord. 2008, 23:942-949.
54. Stamelou M., Pilatus U., Reuss A., Magerkurth J., Eggert K.M., Knake S., Ruberg M., Schade-Brittinger C., Oertel W.H., Hoglinger G.U. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J. Cereb. Blood Flow Metab. 2009, 29:861-870.
55. Stoothoff W., Jones P.B., Spires-Jones T.L., Joyner D., Chhabra E., Bercury K., Fan Z., Xie H., Bacskai B., Edd J., Irimia D., Hyman B.T. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J. Neurochem. 2009, 111:417-427.
56. Taanman J.W., Schapira A.H. Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. Neurosci. Lett. 2005, 376:56-59.
57. Thomas P.K., Cooper J.M., King R.H., Workman J.M., Schapira A.H., Goss-Sampson M.A., Muller D.P. Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. J. Anat. 1993, 183(Pt 3):451-461.
58. Trojanowski J.Q., Lee V.M. Pathological tau: a loss of normal function or a gain in toxicity?. Nat. Neurosci. 2005, 8:1136-1137.
59. Vidal J.S., Vidailhet M., Derkinderen P., de Gaillarbois T.D., Tzourio C., Alperovitch A. Risk factors for progressive supranuclear palsy: a case-control study in France. J. Neurol. Neurosurg. Psychiatry 2009, 80:1271-1274.
60. Vingerhoets F.J., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., Calne D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. 1994, 36:765-770.
61. Warner T.T., Schapira A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 2003, 53(Suppl 3):S16-S23.
62. Yagi T., Matsuno-Yagi A. The proton-translocating NADH-quinone oxidoreductase in the respiratory chain: the secret unlocked. Biochemistry 2003, 42:2266-2274.